has increasingly become a global threat due to its wide range of antifungal resistances as well as its ability to sustain outbreaks in clinical settings. Two lipopeptides, C14-NleRR-NH (Nel) and C14-WRR-NH (WR), were evaluated against six fluconazole-resistant isolates. Both molecules showed good antimicrobial activity as demonstrated by MIC determination, time-kill, and microscopy experiments. The peptides were able to inhibit fungal growth, while sub-MIC concentrations of the molecules delayed the growth. Moreover, the combinations of the two peptides with fluconazole demonstrated a reciprocal potentiation by checkerboard and time-kill experiments. Our results showed that antimicrobial peptides could be a promising option for the treatment of antifungal-resistant .IMPORTANCEAs well as antibiotics, also in fungal infections, antimicrobial resistance increased over the years. Moreover, in the last years, a new species emerged, , as a nosocomial pathogen. possesses intrinsic resistance to common antifungals, such as azoles, that complicate therapeutic options. The combination of these two elements poses a risk for the treatment of fungal infections in the next years. The search for novel compounds with antimicrobial properties is crucial for the treatment of infections to overcome the increasing resistance of these etiological agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1128/spectrum.01786-24 | DOI Listing |
Sci Transl Med
March 2025
Lundquist Institute, Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA.
Mucormycosis is a fungal infection caused by Mucorales fungi that cause severe disease and fatality, especially in immunocompromised individuals. Although vaccines and immunotherapeutics have been successful in combating viral and bacterial infections, approved antifungal immunotherapies are yet to be realized. To address this gap, monoclonal antibodies targeting invasive fungal infections have emerged as a promising approach, particularly for immunocompromised patients who are unlikely to maximally benefit from vaccines.
View Article and Find Full Text PDFSci Adv
March 2025
School of Pharmacy, Lanzhou University, Lanzhou, Gansu 730000, China.
The emergence and rapid spread of multidrug-resistant strains pose a great challenge to the quality and safety of agricultural products and the efficient use of pesticides. Previously unidentified fungicides and targets are urgently needed to combat -associated infections as alternative therapeutic options. In this study, the promising compound Z24 demonstrated efficacy against all tested plant pathogenic fungi.
View Article and Find Full Text PDFArch Dermatol Res
March 2025
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, USA.
Mycoses
March 2025
Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
Background: Candida auris is an emerging fungal pathogen that is often multidrug-resistant. It can persist on skin and in hospital environments, leading to outbreaks and severe infections for patients at risk. Several countries and institutions are working on establishing guidelines and recommendations for prevention.
View Article and Find Full Text PDFInfect Immun
March 2025
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
an invasive basidiomycete fungal pathogen, causes one of the most prevalent, life-threatening diseases in immunocompromised individuals and accounts for ~19% of AIDS-associated deaths. Therefore, understanding the pathogenesis of and its interactions with the host immune system is critical for developing therapeutics against cryptococcosis. Previous studies demonstrated that cells lacking polyphosphate (polyP), an immunomodulatory polyanionic storage molecule, display altered cell surface architecture but unimpaired virulence in a murine model of cryptococcosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!